Literature DB >> 23939995

FGFR1 signaling stimulates proliferation of human mesenchymal stem cells by inhibiting the cyclin-dependent kinase inhibitors p21(Waf1) and p27(Kip1).

Christian Dombrowski1, Torben Helledie, Ling Ling, Martin Grünert, Claire A Canning, C Michael Jones, James H Hui, Victor Nurcombe, Andre J van Wijnen, Simon M Cool.   

Abstract

Signaling through fibroblast growth factor receptor one (FGFR1) is a known inducer of proliferation in both embryonic and human adult mesenchymal stem cells (hMSCs) and positively regulates maintenance of stem cell viability. Leveraging the mitogenic potential of FGF2/FGFR1 signaling in stem cells for therapeutic applications necessitates a mechanistic understanding of how this receptor stimulates cell cycle progression. Using small interfering RNA (siRNA) depletion, antibody-inhibition, and small molecule inhibition, we establish that FGFR1 activity is rate limiting for self-renewal of hMSCs. We show that FGFR1 promotes stem cell proliferation through multiple mechanisms that unite to antagonize cyclin-dependent kinase (CDK) inhibitors. FGFR1 not only stimulates c-Myc to suppress transcription of the CDK inhibitors p21(Waf1) and p27(Kip1), thus promoting cell cycle progression but also increases the activity of protein kinase B (AKT) and the level of S-phase kinase-associated protein 2 (Skp2), resulting in the nuclear exclusion and reduction of p21(Waf1). The in vivo importance of FGFR1 signaling for the control of proliferation in mesenchymal progenitor populations is underscored by defects in ventral mesoderm formation during development upon inhibition of its signaling. Collectively, these studies demonstrate that FGFR1 signaling mediates the continuation of MSC growth and establishes a receptor target for enhancing the expansion of mesenchymal progenitors while maintaining their multilineage potential. © AlphaMed Press.

Entities:  

Keywords:  Adult stem cells; Cell cycle; Cell expansion; Fibroblast growth factor; Heparin-binding

Mesh:

Substances:

Year:  2013        PMID: 23939995     DOI: 10.1002/stem.1514

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  21 in total

Review 1.  Ubiquitination-mediated degradation of cell cycle-related proteins by F-box proteins.

Authors:  Nana Zheng; Zhiwei Wang; Wenyi Wei
Journal:  Int J Biochem Cell Biol       Date:  2016-02-06       Impact factor: 5.085

2.  Role of MSC-derived galectin 3 in the AML microenvironment.

Authors:  Peter P Ruvolo; Vivian R Ruvolo; Jared K Burks; YiHua Qiu; Rui-Yu Wang; Elizabeth J Shpall; Leonardo Mirandola; Numsen Hail; Zhihong Zeng; Teresa McQueen; Naval Daver; Sean M Post; Maurizio Chiriva-Internati; Steven M Kornblau; Michael Andreeff
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-04-12       Impact factor: 4.739

Review 3.  Effects of Physical, Chemical, and Biological Stimulus on h-MSC Expansion and Their Functional Characteristics.

Authors:  David A Castilla-Casadiego; Ana M Reyes-Ramos; Maribella Domenech; Jorge Almodovar
Journal:  Ann Biomed Eng       Date:  2019-11-08       Impact factor: 3.934

4.  Knockdown of the cell cycle inhibitor p21 enhances cartilage formation by induced pluripotent stem cells.

Authors:  Brian O Diekman; Pratiksha I Thakore; Shannon K O'Connor; Vincent P Willard; Jonathan M Brunger; Nicolas Christoforou; Kam W Leong; Charles A Gersbach; Farshid Guilak
Journal:  Tissue Eng Part A       Date:  2015-01-23       Impact factor: 3.845

5.  Decreasing matrix modulus of PEG hydrogels induces a vascular phenotype in human cord blood stem cells.

Authors:  Shruthi Mahadevaiah; Karyn G Robinson; Prathamesh M Kharkar; Kristi L Kiick; Robert E Akins
Journal:  Biomaterials       Date:  2015-05-15       Impact factor: 12.479

6.  FGFR2 accommodates osteogenic cell fate determination in human mesenchymal stem cells.

Authors:  Ying Zhang; Ling Ling; Arya Ajay D/O Ajayakumar; Yating Michelle Eio; Andre J van Wijnen; Victor Nurcombe; Simon M Cool
Journal:  Gene       Date:  2022-01-29       Impact factor: 3.913

7.  Mosaic Activating Mutations in FGFR1 Cause Encephalocraniocutaneous Lipomatosis.

Authors:  James T Bennett; Tiong Yang Tan; Diana Alcantara; Martine Tétrault; Andrew E Timms; Dana Jensen; Sarah Collins; Malgorzata J M Nowaczyk; Marjorie J Lindhurst; Katherine M Christensen; Stephen R Braddock; Heather Brandling-Bennett; Raoul C M Hennekam; Brian Chung; Anna Lehman; John Su; SuYuen Ng; David J Amor; Jacek Majewski; Les G Biesecker; Kym M Boycott; William B Dobyns; Mark O'Driscoll; Ute Moog; Laura M McDonell
Journal:  Am J Hum Genet       Date:  2016-03-03       Impact factor: 11.025

8.  Global MicroRNA Profiling in Human Bone Marrow Skeletal-Stromal or Mesenchymal-Stem Cells Identified Candidates for Bone Regeneration.

Authors:  Chi-Chih Chang; Morten T Venø; Li Chen; Nicholas Ditzel; Dang Q S Le; Philipp Dillschneider; Moustapha Kassem; Jørgen Kjems
Journal:  Mol Ther       Date:  2017-12-05       Impact factor: 11.454

9.  Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.

Authors:  Su-Yang Liu; Nancy M Joseph; Ajay Ravindranathan; Bradley A Stohr; Nancy Y Greenland; Poonam Vohra; Elizabeth Hosfield; Iwei Yeh; Eric Talevich; Courtney Onodera; Jessica A Van Ziffle; James P Grenert; Boris C Bastian; Yunn-Yi Chen; Gregor Krings
Journal:  Mod Pathol       Date:  2016-06-03       Impact factor: 7.842

10.  Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy.

Authors:  Ling Ling; Si Kee Tan; Ting Hwee Goh; Edwin Cheung; Victor Nurcombe; Andre J van Wijnen; Simon M Cool
Journal:  Mol Cancer       Date:  2015-07-23       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.